Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Ovarian Suppression
Interventions: Low dose formulation, High dose formulation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG); Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Healthy
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 6,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: Up to 17 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more

Conditions: Endometrial Cancer
Interventions: medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Ortho-Cyclen, AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions: combined oral contraceptives; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 64 participants
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Female Volunteers
Interventions: PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depression - Major Depressive Disorder, Irritability
Interventions: Kurvelo, Placebo COC; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Drug Interactions
Interventions: BIIB074, OC (ethinyl estradiol and levonorgestrel); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hematologic Malignancies
Interventions: Venetoclax, ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Contraception
Interventions: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 11
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more

Conditions: Healthy Volunteer
Interventions: ABBV-295, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 24
States / cities: Tucson, Arizona • La Mesa, California • San Diego, California + 8 more

Search by objective public record fields.

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Obesity, Oral Contraception, and Ovarian Suppression

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Hormonal Birth Control and the Risk of Acquiring HIV

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

Impact of Combined Hormonal Contraceptives on UPA

Teen Vulnerability to Irritability: Brain and Estrogen Changes

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study